The results of a major clinical trial, examining the effects of chemotherapy on early phase breast cancer, seem likely to have significant implications for the treatment of women with this condition. The trial, conducted at the University of Birmingham, has found that adding Epirubicin to established chemotherapy drugs can noticeably improve survival rates in early stage breast cancer, reducing the risk of death by up to 30%.
Report Abuse
